CA3075908A1 - Immunoassays for detection of ran proteins - Google Patents
Immunoassays for detection of ran proteins Download PDFInfo
- Publication number
- CA3075908A1 CA3075908A1 CA3075908A CA3075908A CA3075908A1 CA 3075908 A1 CA3075908 A1 CA 3075908A1 CA 3075908 A CA3075908 A CA 3075908A CA 3075908 A CA3075908 A CA 3075908A CA 3075908 A1 CA3075908 A1 CA 3075908A1
- Authority
- CA
- Canada
- Prior art keywords
- ran
- poly
- subject
- antibody
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000005912 ran GTP Binding Protein Human genes 0.000 title claims abstract description 149
- 108010005597 ran GTP Binding Protein Proteins 0.000 title claims abstract description 149
- 238000003018 immunoassay Methods 0.000 title claims abstract description 50
- 238000001514 detection method Methods 0.000 title claims description 36
- 239000012472 biological sample Substances 0.000 claims abstract description 71
- 238000000034 method Methods 0.000 claims abstract description 61
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 61
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 40
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 14
- 239000000523 sample Substances 0.000 claims description 61
- 239000003814 drug Substances 0.000 claims description 55
- 229940124597 therapeutic agent Drugs 0.000 claims description 52
- 210000004369 blood Anatomy 0.000 claims description 38
- 239000008280 blood Substances 0.000 claims description 38
- 238000003556 assay Methods 0.000 claims description 36
- 239000013068 control sample Substances 0.000 claims description 10
- 210000004899 c-terminal region Anatomy 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract description 46
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 33
- 201000003498 spinocerebellar ataxia type 36 Diseases 0.000 abstract description 31
- 230000014616 translation Effects 0.000 abstract description 25
- 201000010099 disease Diseases 0.000 abstract description 22
- 239000000203 mixture Substances 0.000 abstract description 3
- 208000023105 Huntington disease Diseases 0.000 description 24
- 238000011282 treatment Methods 0.000 description 20
- 208000024891 symptom Diseases 0.000 description 17
- 239000000427 antigen Substances 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 description 7
- 101710089751 Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000010172 mouse model Methods 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 101150043003 Htt gene Proteins 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 210000001638 cerebellum Anatomy 0.000 description 4
- 210000005153 frontal cortex Anatomy 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 101000603068 Homo sapiens Nucleolar protein 56 Proteins 0.000 description 3
- 206010028289 Muscle atrophy Diseases 0.000 description 3
- 239000012327 Ruthenium complex Substances 0.000 description 3
- -1 Sanofi-Aventis) Chemical compound 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 3
- 229960003805 amantadine Drugs 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000020763 muscle atrophy Effects 0.000 description 3
- 201000000585 muscular atrophy Diseases 0.000 description 3
- 201000009340 myotonic dystrophy type 1 Diseases 0.000 description 3
- 108010054442 polyalanine Proteins 0.000 description 3
- 108010077051 polycysteine Proteins 0.000 description 3
- 108010050934 polyleucine Proteins 0.000 description 3
- 108010000222 polyserine Proteins 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 229960004181 riluzole Drugs 0.000 description 3
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 3
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 206010002942 Apathy Diseases 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- 102000007371 Ataxin-3 Human genes 0.000 description 2
- 108010032947 Ataxin-3 Proteins 0.000 description 2
- 102000007368 Ataxin-7 Human genes 0.000 description 2
- 108010032953 Ataxin-7 Proteins 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 2
- 208000029402 Bulbospinal muscular atrophy Diseases 0.000 description 2
- 201000008163 Dentatorubral pallidoluysian atrophy Diseases 0.000 description 2
- 206010013887 Dysarthria Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000001914 Fragile X syndrome Diseases 0.000 description 2
- 101000701517 Homo sapiens Putative protein ATXN8OS Proteins 0.000 description 2
- 101000915806 Homo sapiens Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B beta isoform Proteins 0.000 description 2
- 101000891654 Homo sapiens TATA-box-binding protein Proteins 0.000 description 2
- 102000016252 Huntingtin Human genes 0.000 description 2
- 108050004784 Huntingtin Proteins 0.000 description 2
- 208000027747 Kennedy disease Diseases 0.000 description 2
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 2
- 206010061296 Motor dysfunction Diseases 0.000 description 2
- 208000008238 Muscle Spasticity Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 102100030469 Putative protein ATXN8OS Human genes 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102100029014 Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B beta isoform Human genes 0.000 description 2
- 208000037140 Steinert myotonic dystrophy Diseases 0.000 description 2
- 102100040296 TATA-box-binding protein Human genes 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 229960000794 baclofen Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
- 229960000623 carbamazepine Drugs 0.000 description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- 231100000867 compulsive behavior Toxicity 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 108010087782 poly(glycyl-alanyl) Proteins 0.000 description 2
- 108010040003 polyglutamine Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- YAYGSLOSTXKUBW-UHFFFAOYSA-N ruthenium(2+) Chemical compound [Ru+2] YAYGSLOSTXKUBW-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 201000003598 spinocerebellar ataxia type 10 Diseases 0.000 description 2
- 201000003570 spinocerebellar ataxia type 17 Diseases 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229960005333 tetrabenazine Drugs 0.000 description 2
- 229960003991 trazodone Drugs 0.000 description 2
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 208000000187 Abnormal Reflex Diseases 0.000 description 1
- 108091026821 Artificial microRNA Proteins 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 102000014461 Ataxins Human genes 0.000 description 1
- 108010078286 Ataxins Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 108010089791 Eukaryotic Initiation Factor-2 Proteins 0.000 description 1
- 108010089790 Eukaryotic Initiation Factor-3 Proteins 0.000 description 1
- 102100027327 Eukaryotic translation initiation factor 2 subunit 2 Human genes 0.000 description 1
- 102100034295 Eukaryotic translation initiation factor 3 subunit A Human genes 0.000 description 1
- 208000002111 Eye Abnormalities Diseases 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- 208000001308 Fasciculation Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000828537 Homo sapiens Synaptic functional regulator FMR1 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 101710158773 L-ascorbate oxidase Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000036700 Oculomotor apraxia Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101000882917 Penaeus paulensis Hemolymph clottable protein Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 229940123773 Phosphodiesterase 10A inhibitor Drugs 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000035955 Proximal myotonic myopathy Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical class [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 102100023532 Synaptic functional regulator FMR1 Human genes 0.000 description 1
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 206010011005 corneal dystrophy Diseases 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 108010077515 glycylproline Proteins 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 206010020745 hyperreflexia Diseases 0.000 description 1
- 230000035859 hyperreflexia Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960001848 lamotrigine Drugs 0.000 description 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
- 229960004577 laquinimod Drugs 0.000 description 1
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 description 1
- 229960004002 levetiracetam Drugs 0.000 description 1
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- 229960003404 mexiletine Drugs 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 201000008709 myotonic dystrophy type 2 Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 206010029864 nystagmus Diseases 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- 229940016084 oleptro Drugs 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- YZPOQCQXOSEMAZ-UHFFFAOYSA-N pbt2 Chemical compound ClC1=CC(Cl)=C(O)C2=NC(CN(C)C)=CC=C21 YZPOQCQXOSEMAZ-UHFFFAOYSA-N 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 description 1
- 229950003764 pridopidine Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 108010004914 prolylarginine Proteins 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000002702 ribosome display Methods 0.000 description 1
- 229940072169 rilutek Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 230000004434 saccadic eye movement Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 201000003517 spinocerebellar ataxia type 29 Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- PMJIHLSCWIDGMD-UHFFFAOYSA-N tideglusib Chemical compound O=C1SN(C=2C3=CC=CC=C3C=CC=2)C(=O)N1CC1=CC=CC=C1 PMJIHLSCWIDGMD-UHFFFAOYSA-N 0.000 description 1
- 229950005284 tideglusib Drugs 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 229960001032 trihexyphenidyl Drugs 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 1
- 229960004751 varenicline Drugs 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/76—Chemiluminescence; Bioluminescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
- G01N2458/30—Electrochemically active labels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plasma & Fusion (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762563009P | 2017-09-25 | 2017-09-25 | |
| US62/563,009 | 2017-09-25 | ||
| PCT/US2018/052745 WO2019060918A1 (en) | 2017-09-25 | 2018-09-25 | IMMUNOLOGICAL ASSAYS FOR DETECTION OF RAN PROTEINS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3075908A1 true CA3075908A1 (en) | 2019-03-28 |
Family
ID=65811531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3075908A Pending CA3075908A1 (en) | 2017-09-25 | 2018-09-25 | Immunoassays for detection of ran proteins |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP3688020A4 (enExample) |
| JP (2) | JP2020535448A (enExample) |
| AU (2) | AU2018338451A1 (enExample) |
| CA (1) | CA3075908A1 (enExample) |
| WO (1) | WO2019060918A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2970884A4 (en) | 2013-03-14 | 2016-11-02 | Univ Florida | DI-AMINO ACID-REINFORCED PROTEINS ASSOCIATED WITH ALS |
| WO2016196324A1 (en) | 2015-05-29 | 2016-12-08 | University Of Floridia Research Foundation, Inc. | Methods for diagnosing huntington's disease |
| US10940161B2 (en) | 2016-04-04 | 2021-03-09 | University Of Florida Research Foundation, Incorporated | Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation |
| JP7526455B2 (ja) | 2017-04-17 | 2024-08-01 | ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． | ＰＫＲおよびｅＩＦ２Ａ－Ｐ経路によるＲＡＮタンパク質翻訳の調節 |
| JP7350337B2 (ja) | 2017-09-26 | 2023-09-26 | ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． | 神経障害の処置においてｒａｎタンパク質レベルを低下させるためのメトホルミンおよびそのアナログの使用 |
| US20220267776A1 (en) * | 2019-07-05 | 2022-08-25 | University Of Florida Research Foundation, Incorporated | Methods for treating ran protein-associated neurological diseases |
| JP7620988B2 (ja) * | 2019-09-20 | 2025-01-24 | ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． | 血清および組織ライセートからのｒａｎタンパク質に対する抗体の検出 |
| US20240069039A1 (en) * | 2019-10-10 | 2024-02-29 | University Of Florida Research Foundation, Incorporated | Ran proteins as biomarkers in cag/ctg expansion disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2082225E (pt) * | 2006-09-20 | 2014-04-10 | Univ Belfast | Método para determinar se uma célula tumoral tem potencial invasivo e/ou metastático e agentes moduladores de transformação maligna |
| MX365235B (es) * | 2010-11-30 | 2019-05-28 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno. |
| EP2970884A4 (en) * | 2013-03-14 | 2016-11-02 | Univ Florida | DI-AMINO ACID-REINFORCED PROTEINS ASSOCIATED WITH ALS |
| CA2990161A1 (en) * | 2014-08-13 | 2016-02-18 | The Scripps Research Institute | Treatment of c9ftd/als by targeting rna expanded repeat sequences |
| JP6508996B2 (ja) * | 2015-03-24 | 2019-05-08 | 東ソー株式会社 | β−ＡＮＰによる心不全の検出方法 |
| AU2016333538B2 (en) * | 2015-10-02 | 2022-03-31 | Julius-Maximilians-Universität Würzburg | GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers |
-
2018
- 2018-09-25 AU AU2018338451A patent/AU2018338451A1/en not_active Abandoned
- 2018-09-25 JP JP2020538771A patent/JP2020535448A/ja active Pending
- 2018-09-25 CA CA3075908A patent/CA3075908A1/en active Pending
- 2018-09-25 EP EP18859783.5A patent/EP3688020A4/en active Pending
- 2018-09-25 WO PCT/US2018/052745 patent/WO2019060918A1/en not_active Ceased
-
2023
- 2023-09-19 JP JP2023150846A patent/JP2023174663A/ja active Pending
-
2024
- 2024-09-04 AU AU2024219412A patent/AU2024219412A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3688020A4 (en) | 2021-07-14 |
| EP3688020A1 (en) | 2020-08-05 |
| JP2020535448A (ja) | 2020-12-03 |
| AU2024219412A1 (en) | 2024-09-26 |
| JP2023174663A (ja) | 2023-12-08 |
| US20200232925A1 (en) | 2020-07-23 |
| AU2018338451A1 (en) | 2020-04-02 |
| WO2019060918A8 (en) | 2019-04-18 |
| WO2019060918A1 (en) | 2019-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2024219412A1 (en) | Immunoassays for detection of ran proteins | |
| CN107099581B (zh) | 预测、诊断和治疗特发性肺纤维化的方法 | |
| Cao et al. | Neuropilin-2 promotes extravasation and metastasis by interacting with endothelial α5 integrin | |
| US8753892B2 (en) | Phosphodiesterase 4D7 as prostate cancer marker | |
| TW201537175A (zh) | 預測罹患具皮膚搔癢之疾病的患者對ｉｌ－３１拮抗劑之治療的反應之方法 | |
| US20240069039A1 (en) | Ran proteins as biomarkers in cag/ctg expansion disorders | |
| JP6240919B2 (ja) | 加齢または筋萎縮の診断用バイオマーカー | |
| KR20240156639A (ko) | 암 진단 및 prmt5 억제제에 의한 치료 | |
| US20160139149A1 (en) | Chi3l1 for the detection and treatment of nonalcoholic steatohepatitis | |
| US12504380B2 (en) | Immunoassays for detection of ran proteins | |
| KR20230081950A (ko) | 갑상선 안병증의 진단을 위한 바이오마커 및 이의 용도 | |
| JP2006520588A (ja) | 治療薬、予防薬、および診断薬 | |
| KR102583540B1 (ko) | 퇴행성 뇌질환에서 zbtb16의 용도 | |
| CN111630185A (zh) | 包含pmvk作为活性成分的用于诊断耐放射癌症或预测放射疗法预后的生物标志物组合物 | |
| JP6341859B2 (ja) | がんマーカーおよびその用途 | |
| KR102179375B1 (ko) | Ctrp3의 건병증 마커 용도 및 ctrp3를 표적으로 하는 건병증 치료용 조성물 및 방법 | |
| US20240210407A1 (en) | Compositions and methods for detecting and treating pathological fibroblast cells | |
| JP2016104716A (ja) | 膵臓癌治療用のｃｄ９５シグナル伝達阻害化合物 | |
| CN117248020B (zh) | Hmgcl作为胶质瘤诊断/预后标志物和治疗靶点的应用 | |
| JP5830329B2 (ja) | 腎障害の新規マーカー | |
| KR102800733B1 (ko) | 담도암의 예방 또는 치료용 조성물 | |
| US20240280590A1 (en) | Compositions and methods for facioscapulohumeral muscular dystrophy biomarker detection | |
| KR20140109956A (ko) | 테나신-c 및 류마티스 관절염에서의 이의 용도 | |
| KR102355205B1 (ko) | 방광암 세포의 이동성 예측용 조성물 및 이를 포함하는 키트 | |
| JP2025077049A (ja) | Ｃａｒｄ１４を用いた治療、診断およびスクリーニング |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230922 |